Cognition Therapeutics, an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, has announced that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program. This cooperative agreement program for Alzheimer's disease translational research will provide Cognition Therapeutics with an estimated $1.4M in funding over four years to support critical drug development activities aimed at securing IND status for the company's first-in-class therapeutics.

Dr. Susan Catalano, founder and chief science officer of Cognition Therapeutics, said, "Our therapeutics have the potential to not only modify behavioral symptoms in patients diagnosed with AD, but to prevent or slow disease progression."

"Small molecule drugs that directly target the binding and pathogenic signaling of soluble oligomers of the Abeta protein represent a potentially important clinical tool to address both the symptoms and disease progression in patients diagnosed with AD," said Dr. Cynthia Lemere, associate professor of Neurology at Harvard Medical School and an associate neuroscientist at Brigham and Women's Hospital in the Center for Neurologic Diseases. "Cognition Therapeutics' novel therapeutic candidates provide renewed hope that we can treat AD in diagnosed patients which is very good news for these patients and their caregivers."